Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGeneration Bio Co

Generation Bio Co

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-03-26T21:08:56.198086Z
Market Cap
204.24M

Momentum Score

…

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.86
Low
6.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
9.96M
Revenue Per Share
0.15
Gross Profit TTM
0.00M
Debt / Equity
0.48
ROE
-82.24%
Net Debt
31.45M
ROCE
-43.70%
Diluted EPS TTM
-2.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -136.64M -119.15M -80.52M -61.32M -35.80M
Net income -132.10M -114.67M -76.50M -60.33M -35.80M
Selling general administrative 44.46M 33.85M 22.58M 12.17M 9.18M
Gross profit - - - - 0.04M
Reconciled depreciation 5.13M 4.53M 3.43M 1.86M 0.35M
Ebit -146.31M -123.63M -84.55M -62.30M -37.29M
Ebitda -141.18M -119.10M -81.11M -60.44M -36.95M
Depreciation and amortization 5.13M 4.53M 3.43M 1.86M 0.35M
Non operating income net other 4.54M -0.05M 0.59M - -
Operating income -141.18M -119.10M -81.11M -62.30M -37.29M
Other operating expenses 141.18M 119.10M 81.11M 62.30M 37.33M
Interest expense 4.54M 0.05M 0.59M 0.00M 0.00M
Interest income 4.54M - - 0.98M 1.49M
Net interest income 4.54M -0.05M 0.59M 0.98M 1.49M
Income tax expense -4.54M -4.48M -4.02M -0.98M 1.49M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.04M
Total operating expenses 141.18M 119.10M 81.11M 62.30M 37.33M
Total other income expense net 4.54M -0.05M 0.59M 0.98M 1.49M
Net income from continuing ops -136.64M -119.15M -80.52M -61.32M -35.80M
Net income applicable to common shares -136.64M -119.15M -80.52M -61.32M -35.80M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 374.76M 376.26M 476.77M 294.15M 42.14M
Other current assets 0.29M 7.53M 4.04M 5.41M 2.63M
Total liab 171.63M 93.77M 95.03M 26.14M 140.73M
Total stockholder equity 203.13M 282.49M 381.75M 268.01M -98.59M
Deferred long term liab - 0.43M 0.46M 0.34M 0.09M
Other current liab 16.53M 11.40M 0.68M 10.95M 6.91M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -571.38M -444.76M -308.13M -188.97M -108.45M
Other liab - - - 14.92M 15.98M
Other assets - 7.83M 6.56M 2.64M 2.14M
Cash 66.45M 93.17M 375.14M 62.89M 15.08M
Total current liabilities 39.91M 19.15M 18.81M 11.22M 9.16M
Current deferred revenue 12.92M - 11.50M - -
Net debt 31.45M -11.46M -294.32M -62.89M -15.08M
Short term debt 8.12M 7.09M 4.61M - -
Short long term debt total 97.89M 81.71M 80.83M - -
Other stockholder equity 774.22M 727.34M 689.87M 162.82M 9.86M
Property plant equipment - 22.21M 25.89M 23.78M 21.84M
Total current assets 272.62M 287.02M 379.19M 267.74M 18.16M
Net tangible assets - 282.49M 381.75M 268.01M -98.59M
Short term investments 197.92M 185.92M 0.00M 199.44M 0.00M
Net receivables 4.15M 0.40M 0.40M 0.25M 0.45M
Inventory 3.82M - - - -
Accounts payable 2.35M 0.66M 2.02M 0.27M 2.25M
Accumulated other comprehensive income 0.27M -0.08M - 0.01M -2.23M
Common stock total equity - 0.01M 0.01M 0.01M 0.00M
Retained earnings total equity - -444.76M -308.13M -188.97M -
Non currrent assets other 0.70M 7.83M 6.56M 2.64M 2.14M
Non current assets total 102.14M 89.25M 97.58M 26.42M 23.98M
Capital lease obligations 97.89M 81.71M 80.83M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -192.51M 198.90M -199.68M 67.89M -69.76M
Change to liabilities -0.59M 3.59M -1.44M 0.76M 0.22M
Total cashflows from investing activities -192.51M 193.05M -205.20M 47.98M -69.76M
Net borrowings - - -0.04M - -
Total cash from financing activities 12.99M 214.67M 323.10M 0.08M 100.19M
Change to operating activities 2.43M 2.42M -0.27M 14.47M 4.46M
Net income -136.64M -119.15M -80.52M -61.32M -35.80M
Change in cash -281.97M 315.90M 47.76M 7.72M 2.31M
Begin period cash flow 380.84M 64.94M 17.18M 9.47M 7.16M
End period cash flow 98.86M 380.84M 64.94M 17.18M 9.47M
Total cash from operating activities -102.45M -91.82M -70.14M -40.35M -28.12M
Issuance of capital stock 12.36M 211.88M 322.75M 0.00M 100.19M
Depreciation 5.13M 4.53M 3.43M 1.86M 0.35M
Other cashflows from investing activities - 0.10M - 67.97M -66.74M
Change to account receivables - - 0.45M - -
Sale purchase of stock 13.57M 214.67M 323.14M 0.10M 100.19M
Other cashflows from financing activities 0.63M 2.79M 109.19M 0.08M 100.19M
Change to netincome 30.30M 18.09M 8.66M 3.88M 2.65M
Capital expenditures 8.80M 5.96M 5.52M 19.99M 3.02M
Cash flows other operating 1.64M 0.59M -3.69M - -
Cash and cash equivalents changes -281.97M 315.90M 47.76M - -
Change in working capital 1.05M 4.17M -1.71M 15.23M 4.68M
Stock based compensation 24.45M 17.86M 8.41M 4.21M 3.49M
Other non cash items 3.56M 0.77M 0.25M -0.32M -0.83M
Free cash flow -111.25M -97.78M -75.66M -60.33M -31.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Generation Bio Co

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

301 Binney Street, Cambridge, MA, United States, 02142

617 655 7500

https://generationbio.com

174

Name Title Year Born
Dr. Cameron Geoffrey McDonough M.D. Pres, CEO, Sec. & Director 1970
Dr. Matthew Norkunas M.B.A., M.D. Chief Financial Officer 1978
Dr. Matthew Stanton Ph.D. Chief Scientific Officer 1973
Dr. Douglas Kerr M.B.A., M.D., Ph.D. Chief Medical Officer 1967
Dr. Tracy Zimmermann Ph.D. Chief Devel. Officer 1970
Dr. Mark D. Angelino Ph.D. Co-Founder 1973
Dr. Robert Kotin Ph.D. Co-Founder & Advisor 1956
Ms. Antionette Paone M.B.A., M.S. Chief Operating Officer 1978
Dr. Jennifer Elliott Esq., J.D., Ph.D. Chief Legal Officer NA
Dr. Phillip Samayoa Ph.D. Chief Strategy Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…